TY - JOUR
T1 - The Co-occurring Syndrome - Coexisting Erectile Dysfunction and Benign Prostatic Hyperplasia and Their Clinical Correlates in Aging Men
T2 - Results from the National Health and Nutrition Examination Survey
AU - Egan, Kathryn B.
AU - Burnett, Arthur L.
AU - McVary, Kevin T.
AU - Ni, Xiao
AU - Suh, Minhyung
AU - Wong, David G.
AU - Rosen, Raymond C.
N1 - Funding Information:
Funding Support: Arthur L. Burnett receives research funding from Endo Pharmaceuticals, Pfizer, the National Institutes of Health, Auxilium Inc, American Medical Systems, Coloplast, Reflexonic LLC, Vivus, Acorda Therapeutics, and Medispec. Kevin T. McVary receives research funding from Allergan, Eli Lilly/ICOS, NxThera, Neotract, the National Institutes for Diabetes and Digestive and Kidney Diseases (NIDDK), Astellas, American Medical Systems and Sophris; and has received speaker fees from GlaxoSmithKline. Raymond C. Rosen receives research funding from Eli Lilly and Company and Bayer Healthcare.The Lilly BPH Publication Initiative was supported by Lilly USA, LLC.
Publisher Copyright:
© 2015 Elsevier Inc. All Rights Reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objective To establish a descriptive profile of men with coexistent erectile dysfunction (ED) and/or benign prostatic hyperplasia (BPH), ED only or BPH only compared to those with neither condition and to identify the determinants of coexisting disease. Materials and Methods Self-report and/or medication use measures defining ED and BPH were assessed in men aged ≥40 years (N = 2142) between 2001 and 2004 using the National Health and Nutrition Examination Surveys. Descriptive analyses examined the ED and/or BPH covariate distribution. Logistic regressions calculated odds ratios (ORs, 95% confidence interval) comparing men with ED and/or BPH, BPH only, or ED only to men with neither condition. Results Of 393 men with BPH, 57.8% had coexistent ED, confirming the moderately strong co-occurrence of the conditions (P <.0001). Coexisting ED and/or BPH occurred in 10.6% of participants, whereas 24.4% and 7.7% reported ED and BPH. After age 60, the odds of reporting ED, BPH, or ED/BPH vs neither almost tripled per decade of increasing age, corresponding to prevalence increases. The unadjusted odds of ED and/or BPH vs no disease increased 1.3 times per prostate-specific antigen unit (ng/mL) increase and 1.1 times per C-reactive protein unit (mg/dL) increase. Other predisposing factors for ED and/or BPH included higher body mass index (OR = 2.5), increased antidiabetic (OR = 2.9) or proton pump inhibitor use (OR = 2.3), increased healthcare visits (≥4; OR = 3.5), and more frequent urinary voiding difficulties (OR = 9.7). Conclusion Co-occurring ED and/or BPH is evident in ∼10% of men ≥40 years old and is associated with significant clinical correlates. Clinicians need to pay greater attention to this clinically important syndrome in aging men.
AB - Objective To establish a descriptive profile of men with coexistent erectile dysfunction (ED) and/or benign prostatic hyperplasia (BPH), ED only or BPH only compared to those with neither condition and to identify the determinants of coexisting disease. Materials and Methods Self-report and/or medication use measures defining ED and BPH were assessed in men aged ≥40 years (N = 2142) between 2001 and 2004 using the National Health and Nutrition Examination Surveys. Descriptive analyses examined the ED and/or BPH covariate distribution. Logistic regressions calculated odds ratios (ORs, 95% confidence interval) comparing men with ED and/or BPH, BPH only, or ED only to men with neither condition. Results Of 393 men with BPH, 57.8% had coexistent ED, confirming the moderately strong co-occurrence of the conditions (P <.0001). Coexisting ED and/or BPH occurred in 10.6% of participants, whereas 24.4% and 7.7% reported ED and BPH. After age 60, the odds of reporting ED, BPH, or ED/BPH vs neither almost tripled per decade of increasing age, corresponding to prevalence increases. The unadjusted odds of ED and/or BPH vs no disease increased 1.3 times per prostate-specific antigen unit (ng/mL) increase and 1.1 times per C-reactive protein unit (mg/dL) increase. Other predisposing factors for ED and/or BPH included higher body mass index (OR = 2.5), increased antidiabetic (OR = 2.9) or proton pump inhibitor use (OR = 2.3), increased healthcare visits (≥4; OR = 3.5), and more frequent urinary voiding difficulties (OR = 9.7). Conclusion Co-occurring ED and/or BPH is evident in ∼10% of men ≥40 years old and is associated with significant clinical correlates. Clinicians need to pay greater attention to this clinically important syndrome in aging men.
UR - http://www.scopus.com/inward/record.url?scp=84941415815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941415815&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2015.04.054
DO - 10.1016/j.urology.2015.04.054
M3 - Article
C2 - 26210004
AN - SCOPUS:84941415815
SN - 0090-4295
VL - 86
SP - 570
EP - 580
JO - Urology
JF - Urology
IS - 3
ER -